NASDAQ:NTEC Intec Pharma - NTEC Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Intec Pharma Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range N/A50-Day Range$9.15▼$36.2052-Week Range N/AVolume988,300 shsAverage Volume543,436 shsMarket Capitalization$8.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Intec Pharma (NASDAQ:NTEC) StockIntec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.Read More Receive NTEC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intec Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address NTEC Stock News HeadlinesMarch 18, 2023 | markets.businessinsider.comMaxim Group Reaffirms Their Buy Rating on Indaptus Therapeutics (INDP)March 2, 2023 | marketwatch.comFibromyalgia Treatment Market Forecast: An Analysis of Industry Trends for 2023-2028March 24, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …February 19, 2023 | marketwatch.comGlobal Parkinson’s Disease Treatment Market Opportunities, Business Statistics Research Report 2030 By VMReportsFebruary 15, 2023 | marketwatch.comFibromyalgia Treatment Market Size 2023 With Over-All Dominated, Share Of Everywhere, Ease Of Access Of SolutionsJanuary 30, 2023 | marketwatch.comSyphilis Rapid Test Kit Market : Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2028January 23, 2023 | marketwatch.comFibromyalgia Treatment Market Industry Updates, New Opportunities, Major Strategies, And Forecast 2028December 29, 2022 | marketwatch.comWith 1.7% CAGR, Fibromyalgia Treatment Market 2023 Is Flourishing Around the World by 2028 | 116 Pages ReportMarch 24, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …December 21, 2022 | marketwatch.comFibromyalgia Treatment Market (New Report) to Witness A Pronounce Growth During 2023-2028 | 116 Pages ReportOctober 17, 2022 | marketwatch.comFibromyalgia Treatment Market Size in 2022 with Latest Report of 100 Pages & Business Forecast up to 2028 by Value Chain Analysis | No of Pages 100August 28, 2022 | marketwatch.comFibromyalgia Treatment Market Size and Share 2022 Analysis Report by Industry Trends, Drivers, Applications, Sale and Forecast to 2028July 5, 2022 | investing.comWorld Holdings Co Ltd (2429)June 4, 2022 | finanznachrichten.deBeroe Inc.: Beroe partners with Mintec to power its intelligence offering with market-leading commodity price dataDecember 18, 2021 | finanznachrichten.deEXEL INDUSTRIES :2020-2021 Full-year results: Significant improvement in margins combined with a sharp reduction in debtDecember 1, 2021 | markets.businessinsider.comGenetron earnings preview: what Wall Street is expectingNovember 12, 2021 | markets.businessinsider.comHere's what Wall Street expects from Cipher Pharmaceuticals's earningsAugust 3, 2021 | finance.yahoo.comIntec Closes Merger with Decoy BiosystemsAugust 3, 2021 | finance.yahoo.comIntec Announces Expected Closing Date of Decoy MergerJuly 29, 2021 | marketwatch.comIntec Parent Shares Up 60%July 26, 2021 | msn.comBRIEF-Intec Announces $30 Mln Private Placement Ahead Of Decoy MergerJuly 26, 2021 | marketwatch.comIntec Pharma in $30 Million Private PlacementJuly 26, 2021 | finance.yahoo.comIntec Announces $30 Million Private Placement Ahead of Decoy MergerJuly 25, 2021 | nasdaq.comIntec Pharma Ltd. Ordinary Shares (NTEC)March 27, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Intec Pharma Ltd. - NTECMarch 23, 2021 | finance.yahoo.comSHAREHOLDER ALERT: WeissLaw LLP Investigates Intec Pharma Ltd.March 22, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Intec Pharma Ltd. MergerSee More Headlines Receive NTEC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intec Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address NTEC Company Calendar Last Earnings5/17/2021Today3/24/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical Preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NTEC CUSIPN/A CIK1638381 Webwww.intecpharma.com Phone(722) 586-4657FaxN/AEmployees40Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($16.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,130,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-96.37% Return on Assets-68.87% Debt Debt-to-Equity RatioN/A Current Ratio2.34 Quick Ratio2.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$16.18 per share Price / BookN/AMiscellaneous Outstanding Shares898,000Free FloatN/AMarket Cap$8.65 million OptionableOptionable Beta0.83 Key ExecutivesJeffrey A. MecklerVice Chairman & Chief Executive OfficerNir SassiPresident & Chief Financial OfficerMichael James NewmanDirector & Chief Scientific OfficerAnna Hotovely-SalomonDirector-Clinical AffairsWalt A. LinscottChief Business OfficerKey CompetitorsEvoke PharmaNASDAQ:EVOKOncorusNASDAQ:ONCRAthenexNASDAQ:ATNXBiophytisNASDAQ:BPTSVYNE TherapeuticsNASDAQ:VYNEView All Competitors NTEC Stock - Frequently Asked Questions How were Intec Pharma's earnings last quarter? Intec Pharma Ltd (NASDAQ:NTEC) announced its quarterly earnings results on Monday, May, 17th. The biotechnology company reported ($3.84) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($3.48) by $0.36. When did Intec Pharma's stock split? Intec Pharma's stock reverse split on Tuesday, July 27th 2021. The 1-4 reverse split was announced on Tuesday, July 27th 2021. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. What other stocks do shareholders of Intec Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intec Pharma investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Nabriva Therapeutics (NBRV), Onconova Therapeutics (ONTX), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), T2 Biosystems (TTOO) and Acasti Pharma (ACST). When did Intec Pharma IPO? (NTEC) raised $30 million in an initial public offering on Tuesday, August 4th 2015. The company issued 5,000,000 shares at a price of $6.00 per share. Maxim Group and Roth Capital Partners acted as the underwriters for the IPO. What is Intec Pharma's stock symbol? Intec Pharma trades on the NASDAQ under the ticker symbol "NTEC." How much money does Intec Pharma make? Intec Pharma (NASDAQ:NTEC) has a market capitalization of $0.00. The biotechnology company earns $-14,130,000.00 in net income (profit) each year or ($16.32) on an earnings per share basis. How can I contact Intec Pharma? Intec Pharma's mailing address is 12 HARTOM STREET HAR HOTZVIM, JERUSALEM L3, 777512. The official website for the company is www.intecpharma.com. The biotechnology company can be reached via phone at (722) 586-4657 or via email at ir@intec-us.com. This page (NASDAQ:NTEC) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.